Strategic Acquisition Evaluation
Full-spectrum acquisition evaluation. Synergy bridge, competitive impact, integration risk — board-ready in one pass.
A Verdict workproduct
Sample output from a Corporate M&A run. Synthetic deal, real workproduct shape.
| Synergy | Mgmt | Cortix base | Delta |
|---|---|---|---|
| Cost — operations | $80M | $52M | -$28M |
| Cost — corporate | $40M | $36M | -$4M |
| Revenue — cross-sell | $60M | $24M | -$36M |
Mgmt $180M = 5.0% of combined revenue. Top-quartile precedent: 3.8%. Cortix base case: $112M.
Acquire at $1.65B or below. Build the synergy case to $112M evidence-supported. Factor competitor counterfactual cost into willingness-to-pay. Plan for second-request in EU/UK with a 9-month buffer.
Corporate development teams evaluating acquisitions. Boards reviewing M&A authorizations. CFOs and CEOs preparing for shareholder communications. Strategic advisors providing independent analysis alongside investment banks.